Does Demant A/S (CPH:DEMANT) Have A Good P/E Ratio?

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Demant A/S's (CPH:DEMANT), to help you decide if the stock is worth further research. Demant has a price to earnings ratio of 37.58, based on the last twelve months. In other words, at today's prices, investors are paying DKK37.58 for every DKK1 in prior year profit.

Check out our latest analysis for Demant

Advertisement

How Do I Calculate Demant's Price To Earnings Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Or for Demant:

P/E of 37.58 = DKK225.60 ÷ DKK6.00 (Based on the trailing twelve months to December 2019.)

Is A High Price-to-Earnings Ratio Good?

A higher P/E ratio means that buyers have to pay a higher price for each DKK1 the company has earned over the last year. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

How Does Demant's P/E Ratio Compare To Its Peers?

We can get an indication of market expectations by looking at the P/E ratio. The image below shows that Demant has a lower P/E than the average (46.1) P/E for companies in the medical equipment industry.

CPSE:DEMANT Price Estimation Relative to Market, February 22nd 2020
CPSE:DEMANT Price Estimation Relative to Market, February 22nd 2020

Demant's P/E tells us that market participants think it will not fare as well as its peers in the same industry. Since the market seems unimpressed with Demant, it's quite possible it could surprise on the upside. If you consider the stock interesting, further research is recommended. For example, I often monitor director buying and selling.

How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. Earnings growth means that in the future the 'E' will be higher. And in that case, the P/E ratio itself will drop rather quickly. Then, a lower P/E should attract more buyers, pushing the share price up.

Demant shrunk earnings per share by 18% over the last year. But over the longer term (5 years) earnings per share have increased by 4.7%.

Don't Forget: The P/E Does Not Account For Debt or Bank Deposits

One drawback of using a P/E ratio is that it considers market capitalization, but not the balance sheet. Thus, the metric does not reflect cash or debt held by the company. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

While growth expenditure doesn't always pay off, the point is that it is a good option to have; but one that the P/E ratio ignores.

How Does Demant's Debt Impact Its P/E Ratio?

Demant's net debt is 13% of its market cap. This could bring some additional risk, and reduce the number of investment options for management; worth remembering if you compare its P/E to businesses without debt.

The Verdict On Demant's P/E Ratio

Demant's P/E is 37.6 which is above average (16.8) in its market. With modest debt but no EPS growth in the last year, it's fair to say the P/E implies some optimism about future earnings, from the market.

When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About CPSE:DEMANT

Demant

Operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally.

Undervalued with reasonable growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’sMost Mispriced AI Story

Fair Value:US$7.551.2% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56053.9% undervalued
50 users have followed this narrative
2 users have commented on this narrative
28 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2782.0% undervalued
17 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
RCKT logo
AnimalDoctorKwon on Rocket Pharmaceuticals ·

The Structural Disconnect Between Market Valuation and Operational Maturity

Fair Value:US$1066.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
AKBA logo
AnimalDoctorKwon on Akebia Therapeutics ·

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Fair Value:US$77.2998.6% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
MBIO logo
AnimalDoctorKwon on Mustang Bio ·

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Fair Value:US$1.861.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.6% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9638.3% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17057.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative